AKT1 and colorectal carcinoma: TVB-3664 hindered tumor formation in CRC cells and the patient-derived xenograft (PDX) model by manipulating the AKT and Erk1/2 cancer-promoting pathways, leading to the altered lipid composition of tumors and indicating its possible therapeutic significance [196].